Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma

(2020) Fredrik Schjesvold et al.   Future Oncology

Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study

(2020) Hiroyuki Takamatsu et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

(2020) Paul G Richardson et al.   Lancet Haematology

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

(2019) Philippe Moreau et al.   Blood Cancer Journal

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

(2019) Ujjawal H. Gandhi et al.   LEUKEMIA

Use of novel therapies in the treatment of light chain amyloidosis

(2019) Cindy Varga et al.   BLOOD REVIEWS

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current status of autologous stem cell transplantation for multiple myeloma

(2019) Rama Al Hamed et al.   Blood Cancer Journal

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

(2019) Philippe Moreau et al.   LANCET

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

(2019) Enrique M. Ocio et al.   BLOOD

A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

(2019) Shaji Kumar et al.   Clinical Lymphoma Myeloma & Leukemia

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

(2019) Mattia D’Agostino et al.   LEUKEMIA

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

New concepts in the treatment and diagnosis of amyloidosis

(2018) Paolo Milani et al.   Expert Review of Hematology

Drug resistance in multiple myeloma

(2018) Pawel Robak et al.   CANCER TREATMENT REVIEWS

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities

(2018) Agne Paner et al.   Expert Review of Hematology

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

(2018) Paul G. Richardson et al.   Blood Cancer Journal

Systemic immunoglobulin light chain amyloidosis

(2018) Giampaolo Merlini et al.   Nature Reviews Disease Primers

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Which therapies will move to the front line for multiple myeloma?

(2017) María J Cejalvo et al.   Expert Review of Hematology

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

(2017) M Chin et al.   Blood Cancer Journal

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

(2017) Malin Wickström et al.   Oncotarget

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

(2016) Saad Z. Usmani et al.   BLOOD

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

(2016) M. A. Dimopoulos et al.   BLOOD

In vitro and in vivo activity of melflufen (J1) in lymphoma

(2016) Maryam Delforoush et al.   BMC CANCER

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

(2016) Arghya Ray et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multiple myeloma: patient outcomes in real-world practice

(2016) Kwee Yong et al.   BRITISH JOURNAL OF HAEMATOLOGY

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

(2016) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia

(2016) Sara Strese et al.   Oncotarget

Preclinical activity of melflufen (J1) in ovarian cancer

(2016) Charlotte Carlier et al.   Oncotarget

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

(2015) Åke Berglund et al.   INVESTIGATIONAL NEW DRUGS

Positioning of aminopeptidase inhibitors in next generation cancer therapy

(2014) Sarina M. Hitzerd et al.   AMINO ACIDS

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Romiplostim for management of chemotherapy-induced thrombocytopenia

(2014) R. Parameswaran et al.   SUPPORTIVE CARE IN CANCER

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo

(2013) Sara Strese et al.   BIOCHEMICAL PHARMACOLOGY

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

(2013) D. Chauhan et al.   CLINICAL CANCER RESEARCH

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

(2012) M. Chesi et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan

(2010) Malin Wickström et al.   BIOCHEMICAL PHARMACOLOGY

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy

(2010) Christa E. Nath et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Aminopeptidase N (CD13) as a target for cancer chemotherapy

(2010) Malin Wickström et al.   CANCER SCIENCE

Novel Melphalan and Chlorambucil Derivatives of 2,2,6,6-Tetramethyl-1-piperidinyloxy Radicals: Synthesis, Characterization, and Biological Evaluation in Vitro

(2010) Hongli Zhao et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE